Pharmacogenomics and Drug Screening Lead to a Novel Targeted Therapy with Potent and Specific Activity Against Mouse Models of MYCN-amplified Neuroblastoma |
Virginia Commonwealth University / Anthony Faber, MD & Yael Mosse, MD (CHOP) |
Innovation Grants |
2015 |
Virginia |
The TC3 Line, a Zebrafish Model of T-Cell Malignancy
|
Huntsman Cancer Institute / Nathan Meeker, MD |
Young Investigator Grants |
2008 |
Utah |
A novel compound for treatment of T cell leukemia |
Huntsman Cancer Institute / Nikolaus Trede |
Innovation Grants |
2010 |
Utah |
Targeting Metabolism in Alveolar Soft Part Sarcomagenesis |
Huntsman Cancer Institute / Kevin Jones, MD |
'A' Award Grants |
2013 |
Utah |
Comprehensive Analysis of Risk Factors for Pediatric Cancers Using the Utah Population Database |
Huntsman Cancer Institute / Joshua Schiffman, MD |
Epidemiology Grants |
2012 |
Utah |
Comprehensive Analysis of Risk Factors for Pediatric Cancers Using the Utah Population Database |
Huntsman Cancer Institute / Joshua Schiffman, MD |
Epidemiology Grants |
2010 |
Utah |
Ectopic Neuroligin Signaling in Pediatric Glioblastoma |
University of Utah / Alex Shcheglovitov, PhD |
Innovation Grants |
2023 |
Utah |
Determining Social Risk Factors for Poor Outcomes in Pediatric Cancer Using Children’s Oncology Group Registries |
University of Utah / Anne Kirchhoff, PhD/MPH |
Epidemiology Grants |
2019 |
Utah |
Is SIRT5 a Therapy Target in Acute Lymphoblastic Leukemia? |
University of Utah / Michael Deininger, MD/PhD |
Innovation Grants |
2018 |
Utah |
GSTM4, a novel target for treating Ewing sarcoma.
|
Huntsman Cancer Institute / Wen Luo |
Young Investigator Grants |
2009 |
Utah |